158 related articles for article (PubMed ID: 38132253)
21. Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients: impact on biomarker testing.
Pérez-Barrios C; Nieto-Alcolado I; Torrente M; Jiménez-Sánchez C; Calvo V; Gutierrez-Sanz L; Palka M; Donoso-Navarro E; Provencio M; Romero A
Transl Lung Cancer Res; 2016 Dec; 5(6):665-672. PubMed ID: 28149760
[TBL] [Abstract][Full Text] [Related]
22. Cell-free DNA extraction from urine of lung cancer patients and healthy individuals: Evaluation of a simple method using sample volume up-scaling.
Ruppert T; Roth A; Kollmeier J; Mairinger T; Frost N
J Clin Lab Anal; 2023 Nov; 37(21-22):e24984. PubMed ID: 37991151
[TBL] [Abstract][Full Text] [Related]
23. Liquid biopsy for detection of EGFR T790M mutation in nonsmall cell lung cancer: An experience of proficiency testing in Taiwan.
Ho HL; Huang CC; Ku WH; Ho CL; Lin CH; Yu SL; Chou TY
J Chin Med Assoc; 2019 Jun; 82(6):473-476. PubMed ID: 30932938
[TBL] [Abstract][Full Text] [Related]
24. Circulating tumor DNA measurement provides reliable mutation detection in mice with human lung cancer xenografts.
Wei L; Xie L; Wang X; Ma H; Lv L; Liu L; Song X
Lab Invest; 2018 Jul; 98(7):935-946. PubMed ID: 29497175
[TBL] [Abstract][Full Text] [Related]
25. Comparison of methods for donor-derived cell-free DNA quantification in plasma and urine from solid organ transplant recipients.
Kueng N; Arcioni S; Sandberg F; Kuhn C; Banz V; Largiadèr CR; Sidler D; Amstutz U
Front Genet; 2023; 14():1089830. PubMed ID: 36777723
[TBL] [Abstract][Full Text] [Related]
26. Application of CRISPR/Cas9-based mutant enrichment technique to improve the clinical sensitivity of plasma EGFR testing in patients with non-small cell lung cancer.
Kim B; Kim Y; Shin S; Lee ST; Cho JY; Lee KA
Cancer Cell Int; 2022 Feb; 22(1):82. PubMed ID: 35168603
[TBL] [Abstract][Full Text] [Related]
27. Clinical Significance of Hotspot Mutation Analysis of Urinary Cell-Free DNA in Urothelial Bladder Cancer.
Hayashi Y; Fujita K; Matsuzaki K; Eich ML; Tomiyama E; Matsushita M; Koh Y; Nakano K; Wang C; Ishizuya Y; Kato T; Hatano K; Kawashima A; Ujike T; Uemura M; Imamura R; Netto GJ; Nonomura N
Front Oncol; 2020; 10():755. PubMed ID: 32509577
[TBL] [Abstract][Full Text] [Related]
28. Detection of Plasma EGFR Mutations in NSCLC Patients with a Validated ddPCR Lung cfDNA Assay.
Guo QM; Wang L; Yu WJ; Qiao LH; Zhao MN; Hu XM; Sun YM; Ni S; Xu YH; Lou JT
J Cancer; 2019; 10(18):4341-4349. PubMed ID: 31413754
[No Abstract] [Full Text] [Related]
29. Optimal method for quantitative detection of plasma EGFR T790M mutation using droplet digital PCR system.
Suzawa K; Yamamoto H; Ohashi K; Hashida S; Tomida S; Kubo T; Maki Y; Soh J; Tsukuda K; Kiura K; Miyoshi S; Toyooka S
Oncol Rep; 2017 May; 37(5):3100-3106. PubMed ID: 28405680
[TBL] [Abstract][Full Text] [Related]
30. Plasma Cell-Free DNA Testing of Patients With EGFR Mutant Non-Small-Cell Lung Cancer: Droplet Digital PCR Versus Next-Generation Sequencing Compared With Tissue-Based Results.
Steendam CMJ; Atmodimedjo P; de Jonge E; Paats MS; van der Leest C; Oomen-de Hoop E; Jansen MPHM; Del Re M; von der Thüsen JH; Dinjens WNM; van Schaik RHN; Aerts JGJV; Dubbink HJ;
JCO Precis Oncol; 2019 Dec; 3():1-9. PubMed ID: 35100738
[TBL] [Abstract][Full Text] [Related]
31. An improved digital polymerase chain reaction protocol to capture low-copy KRAS mutations in plasma cell-free DNA by resolving 'subsampling' issues.
Ono Y; Sugitani A; Karasaki H; Ogata M; Nozaki R; Sasajima J; Yokochi T; Asahara S; Koizumi K; Ando K; Hironaka K; Daito T; Mizukami Y
Mol Oncol; 2017 Oct; 11(10):1448-1458. PubMed ID: 28691390
[TBL] [Abstract][Full Text] [Related]
32. Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing.
Medina Diaz I; Nocon A; Mehnert DH; Fredebohm J; Diehl F; Holtrup F
PLoS One; 2016; 11(11):e0166354. PubMed ID: 27832189
[TBL] [Abstract][Full Text] [Related]
33. Validation and comparison of two NGS assays for the detection of EGFR T790M resistance mutation in liquid biopsies of NSCLC patients.
Vollbrecht C; Lehmann A; Lenze D; Hummel M
Oncotarget; 2018 Apr; 9(26):18529-18539. PubMed ID: 29719623
[TBL] [Abstract][Full Text] [Related]
34. Impact of Preanalytical and Analytical Methods on Cell-Free DNA Diagnostics.
Krasic J; Abramovic I; Vrtaric A; Nikolac Gabaj N; Kralik-Oguic S; Katusic Bojanac A; Jezek D; Sincic N
Front Cell Dev Biol; 2021; 9():686149. PubMed ID: 34552921
[TBL] [Abstract][Full Text] [Related]
35. Molecular Analysis of Circulating Cell-Free DNA from Lung Cancer Patients in Routine Laboratory Practice: A Cross-Platform Comparison of Three Different Molecular Methods for Mutation Detection.
Bartels S; Persing S; Hasemeier B; Schipper E; Kreipe H; Lehmann U
J Mol Diagn; 2017 Sep; 19(5):722-732. PubMed ID: 28723342
[TBL] [Abstract][Full Text] [Related]
36. Selective gene amplification to detect the T790M mutation in plasma from patients with advanced non-small cell lung cancer (NSCLC) who have developed epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance.
Nishikawa S; Kimura H; Koba H; Yoneda T; Watanabe S; Sakai T; Hara J; Sone T; Kasahara K; Nakao S
J Thorac Dis; 2018 Mar; 10(3):1431-1439. PubMed ID: 29707292
[TBL] [Abstract][Full Text] [Related]
37. Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma.
Su KY; Tseng JS; Liao KM; Yang TY; Chen KC; Hsu KH; Yang PC; Yu SL; Chang GC
PLoS One; 2018; 13(11):e0207001. PubMed ID: 30444875
[TBL] [Abstract][Full Text] [Related]
38. Multiplex picoliter-droplet digital PCR for quantitative assessment of EGFR mutations in circulating cell-free DNA derived from advanced non-small cell lung cancer patients.
Yu Q; Huang F; Zhang M; Ji H; Wu S; Zhao Y; Zhang C; Wu J; Wang B; Pan B; Zhang X; Guo W
Mol Med Rep; 2017 Aug; 16(2):1157-1166. PubMed ID: 29067441
[TBL] [Abstract][Full Text] [Related]
39. Selecting short length nucleic acids localized in exosomes improves plasma
Kim Y; Shin S; Kim B; Lee KA
Cancer Cell Int; 2019; 19():251. PubMed ID: 31582907
[TBL] [Abstract][Full Text] [Related]
40. Investigation of appropriate pre-analytical procedure for circulating free DNA from liquid biopsy.
Sato A; Nakashima C; Abe T; Kato J; Hirai M; Nakamura T; Komiya K; Kimura S; Sueoka E; Sueoka-Aragane N
Oncotarget; 2018 Aug; 9(61):31904-31914. PubMed ID: 30159131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
